glp 1 agonist cardiovascular outcomes GLP-1 Receptor Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes Kidney and Cardiovascular Outcomes Among

Background: Type 2 diabetes mellitus (T2D) is associated with an increased fracture risk

You may still be a candidate for the Fitish Microdosing program, a lower dose option for patients who want a gentler, cosmetic approach

How retatrutide works: the first triple agonist targeting GIP, GLP-1, and glucagon receptors

Glycemic monitoring with CGMs, glucose-lowering agents (GLP-1 receptor agonists), innovative insulin delivery systems, and mental health check-ins are just a few updates to the ADA 2025 Standards of Care.

Gastrointestinal (GI) adverse eventsparticularly nausea, vomiting, diarrhea, and constipationare the most common side effects, generally emerging during dose escalation and resolving over time